newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

  • Cogent Biosciences will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 10, 2026 at 7:30 a.m. ET.
  • A live webcast of the event will be available on the company's Investors & Media page, with a replay accessible approximately two hours post-event for up to 30 days.
  • On October 26, 2026, the independent Compensation Committee approved inducement equity awards for six new employees under the 2020 Inducement Plan.
  • The approved grants include nonqualified options for 22,000 shares & 16,500 restricted stock units (RSUs) in aggregate.
  • Each option has a 10-year term, an exercise price equal to the closing stock price on the grant date, & a 4-year vesting schedule starting with 25% on the 1-year anniversary.
  • The RSUs vest annually in equal installments over 4 years, contingent on continued employment through each vesting date.
  • The company's lead clinical candidate, bezuclastinib, is a selective tyrosine kinase inhibitor targeting the KIT D816V mutation responsible for Systemic Mastocytosis & exon 17 mutations in Gastrointestinal Stromal Tumors.
  • Cogent is also developing a portfolio of targeted therapies for mutations in ErbB2, PI3Kα, KRAS, & JAK2.
  • The company is headquartered in Waltham, MA & Boulder, CO.